See the DrugPatentWatch profile for Cyramza
What is Cyramza, and what antibody is it?
Cyramza is the brand name for ramucirumab, a monoclonal antibody that targets the VEGFR-2 (vascular endothelial growth factor receptor 2) on cancer cells and tumor blood vessels, helping slow tumor growth by disrupting tumor angiogenesis.
What cancer types is Cyramza (ramucirumab) used for?
Cyramza is used in multiple settings, including cancers where blocking VEGF/VEGFR signaling can reduce tumor blood supply. Common clinical use areas include gastric or gastroesophageal junction cancer and non-small cell lung cancer (NSCLC) in specific combinations/lines of therapy (depending on tumor characteristics and prior treatment).
How is ramucirumab (Cyramza) different from other VEGF/VEGFR antibodies?
Ramucirumab is specifically an anti-VEGFR-2 antibody (it blocks the receptor). Other angiogenesis agents may target VEGF ligand (for example, anti-VEGF drugs) rather than the receptor. This difference matters because it changes the biology of what signaling step is blocked.
Who makes Cyramza, and what patents/exclusivity affect it?
Cyramza is marketed by its manufacturer(s) in different regions, and its ability for competing products to enter can depend on patents and exclusivity terms for ramucirumab and related formulations/uses. For patent tracking and timing signals, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/
What side effects do patients ask about with Cyramza?
Patients commonly ask about side effects related to angiogenesis inhibition and infusion therapy, such as hypertension, bleeding risk, blood clots, fatigue, and protein in the urine (proteinuria). Exact risk varies by regimen and patient factors.
Can biosimilars or generics replace Cyramza?
Because Cyramza is a biologic monoclonal antibody, replacement products are typically biosimilars, not standard small-molecule generics. Entry timing depends on patent and regulatory exclusivity status. For up-to-date timing/patent details, check DrugPatentWatch.com: https://www.drugpatentwatch.com/
If you meant a different “Cyramza antibody” question, which one?
People search “Cyramza antibody” for different reasons. Tell me which you want:
- the target and mechanism (VEGFR-2),
- what cancers it treats and in what combinations,
- dosing schedule,
- major side effects and monitoring,
- or whether biosimilars/patent expiry apply.
Sources
- https://www.drugpatentwatch.com/